Beta-interferon exposure and onset of secondary progressive multiple sclerosis

European Journal of Neurology

Volumn 22, Issue 6, 2015, Pages 990-1000

  Zhang, T ^a   Shirani, A ^b   Zhao, Y ^c   Karim, M E ^c   Gustafson, P ^c   Petkau, J ^c   Evans, C ^d   Kingwell, E ^a   van der Kop, M ^e   Zhu, F ^a   Oger, J ^a   Tremlett, H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Beta interferon; Cohort study; Multiple sclerosis; Progression

Indexed keywords

BETA INTERFERON; GLATIRAMER;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DRUG EXPOSURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SOCIAL STATUS; CANADA; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; BRITISH COLUMBIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84928359255     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12698     Document Type: Article

References (39)

1. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005; 81: 302-308.
2. The Multiple Sclerosis International Federation. An Atlas of MS. http://www.atlasofms.org/ (accessed 19/09/2013).
3. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74: 2004-2015.
4. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14: 314-324.
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
6. Ann Marrie R, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006; 2: 34-44.
7. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51.
8. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-552.
9. La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012; 1: CD005181.
10. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.
11. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 2012; 19: 765-774.
12. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2012; PMID: 22653657 [Epub ahead of print].
13. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis . Ann Neurol 2008; 64: 109-110.
14. Koch M, Mostert J, De Keyser J, Tremlett H, Filippini G. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol 2008; 63: 125-126.
15. Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler 2012; 18: 1534-1540.
16. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992; 42: 991-994.
17. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73: 1616-1623.
18. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247-256.
19. BC Ministry of Health [creator] (2010): PharmaNet. BC Ministry of Health [publisher]. Data Extract. Data Stewardship Committee (2010). http://www.popdata.bc.ca/data (accessed 19/03/2015).
20. British Columbia Ministry of Health [creator] (2010): Medical Services Plan (MSP) Payment Information File. Population Data BC [publisher]. Data Extract. MOH (2010). http://www.popdata.bc.ca/data (accessed 19/03/2015).
21. British Columbia Ministry of Health [creator] (2010): Discharge Abstract Database (Hospital Separations). Population Data BC [publisher]. Data Extract. MOH (2010). http://www.popdata.bc.ca/data (accessed 19/03/2015).
22. British Columbia Ministry of Health [creator] (2009): Consolidation File (MSP Registration and Premium Billing). Population Data BC [publisher]. Data Extract. MOH (2009). http://www.popdata.bc.ca/data (accessed 19/03/2015).
23. Wilkins R, Berthelot JM, Ng E. Trends in mortality by neighbourhood income in urban Canada from 1971 to 1996. Health Rep 2002; 13(Suppl): 1-27.
24. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
25. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
26. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010; 81: 907-912.
27. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
28. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
30. Shirani A, Zhao Y, Karim ME, et al. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Eur J Neurol 2013; 21: 835-844.
31. British Columbia Ministry of Health [creator] (2009): Adjusted Clinical Groups. Population Data BC [publisher]. Data Extract. Version 5. MOH (2011). http://www.popdata.bc.ca/data (accessed 19/03/2015).
32. R Core Team. R: A Language and Environment for Statistical Computing, Version 3.0.2. Vienna, Austria: R Foundation for Statistical Computing, 2013. http://www.R-project.org/. [computer program].
33. Goodkin DE. Interferon beta treatment for multiple sclerosis: persisting questions. Mult Scler 1996; 1: 321-324.
34. Rolak LA. IFNB in MS. Neurology 1996; 47: 1110.
35. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011; 4: 363-371.
36. Marrie RA. Observational studies of treatment effectiveness: useful, useless or somewhere in between? Mult Scler 2013; 19: 707-708.
37. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011; 305: 2462-2463.
38. Sorensen PS. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord 2008; 1: 125-141.
39. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.